Cargando…

Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer

Gastric cancer is one of the most common types of human cancer associated with a poor prognosis. MicroRNAs (miRs), a class of non-coding RNAs that are 18–25 nucleotides in length, act as key regulators in gene expression, and have been implicated in various human cancer types. miR-125b has been impl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sui, Minghua, Jiao, Aihong, Zhai, Huiyuan, Wang, Yan, Wang, Yong, Sun, Dengjun, Li, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488498/ https://www.ncbi.nlm.nih.gov/pubmed/28672982 http://dx.doi.org/10.3892/etm.2017.4548

Ejemplares similares

miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
por: Ninio-Many, Lihi, et al.
Publicado: (2020)

Low expression of miR-125a-5p is associated with poor prognosis in patients with gastric cancer
por: Li, Guan, et al.
Publicado: (2019)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Plasma miR‐125a and miR‐125b in sepsis: Correlation with disease risk, inflammation, severity, and prognosis
por: Zhao, Danna, et al.
Publicado: (2020)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Upregulation of KIF20A correlates with poor prognosis in gastric cancer
por: Sheng, Yi, et al.
Publicado: (2018)

Upregulation of FGD6 Predicts Poor Prognosis in Gastric Cancer
por: Zeng, Jianmin, et al.
Publicado: (2021)

Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type
por: Xu, Chen, et al.
Publicado: (2017)

Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma
por: Bai, Ming, et al.
Publicado: (2017)

Flotillin2 Expression Correlates with HER2 Levels and Poor Prognosis in Gastric Cancer
por: Zhu, Zhi, et al.
Publicado: (2013)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Upregulation of miR-1269 Contributes to the Progression of Esophageal Squamous Cell Cancer Cells and Is Associated With Poor Prognosis
por: Bai, Xiuhui, et al.
Publicado: (2021)

MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
por: Ye, Xingming, et al.
Publicado: (2014)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
por: Castro-Guijarro, Ana Carla, et al.
Publicado: (2023)

miR-20b overexpression is predictive of poor prognosis in gastric cancer
por: Xue, Tong-min, et al.
Publicado: (2015)

Upregulation of ZHX2 predicts poor prognosis and is correlated with immune infiltration in gastric cancer
por: Cheng, Anqi, et al.
Publicado: (2021)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2014)

High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
por: Liu, Yu-Lin, et al.
Publicado: (2015)

Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells
por: Ichikawa, Takehiro, et al.
Publicado: (2012)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
por: Kong, Xiangyi, et al.
Publicado: (2019)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Upregulated expression of miR-421 is associated with poor prognosis in non-small-cell lung cancer
por: Li, Yunxia, et al.
Publicado: (2018)

Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-Small-Cell Lung Cancer
por: Liu, Fayong, et al.
Publicado: (2021)

Upregulation of Cullin 4B Promotes Gastric Cancer and Predicts Poor Prognosis
por: Wu, Ping, et al.
Publicado: (2020)

MiR‐125b but not miR‐125a is upregulated and exhibits a trend to correlate with enhanced disease severity, inflammation, and increased mortality in sepsis patients
por: Zhu, Xiaoping
Publicado: (2019)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Downregulation of miR-484 is associated with poor prognosis and tumor progression of gastric cancer
por: Li, Ying, et al.
Publicado: (2020)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells
por: Noyan, Senem, et al.
Publicado: (2019)

miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer
por: Tang, Hailin, et al.
Publicado: (2019)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
por: Che, Yi-Qun, et al.
Publicado: (2019)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer
por: Vilquin, Paul, et al.
Publicado: (2015)

miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer
por: Guo, Jing, et al.
Publicado: (2021)

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
por: Gijsen, M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6cajp9sr7ng0d5aktttatl4tf6